Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Biomarker-Driven Therapeutic Management of Alzheimer’s Disease: Establishing the Foundations
Authors
Keywords
-
Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 95, Issue 1, Pages 67-77
Publisher
Springer Nature
Online
2013-10-08
DOI
10.1038/clpt.2013.205
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CSF biomarker variability in the Alzheimer's Association quality control program
- (2013) Niklas Mattsson et al. Alzheimers & Dementia
- 2013 Alzheimer's disease facts and figures
- (2013) Alzheimers & Dementia
- High-Dose Donepezil (23 mg/day) for the Treatment of Moderate and Severe Alzheimer's Disease: Drug Profile and Clinical Guidelines
- (2013) Jeffrey L. Cummings et al. CNS Neuroscience & Therapeutics
- Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study
- (2013) Victor L Villemagne et al. LANCET NEUROLOGY
- Clinical Trials in Predementia Stages of Alzheimer Disease
- (2013) Jagan A. Pillai et al. MEDICAL CLINICS OF NORTH AMERICA
- Cerebral atrophy in mild cognitive impairment and Alzheimer disease: Rates and acceleration
- (2013) K. K. Leung et al. NEUROLOGY
- Brain -amyloid load approaches a plateau
- (2013) C. R. Jack et al. NEUROLOGY
- Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
- (2013) Benjamin Lam et al. Alzheimers Research & Therapy
- The Genetics of Alzheimer Disease
- (2013) R. E. Tanzi Cold Spring Harbor Perspectives in Medicine
- Fluid Biomarkers in Alzheimer Disease
- (2013) K. Blennow et al. Cold Spring Harbor Perspectives in Medicine
- 2012 Alzheimer’s disease facts and figures
- (2012) Alzheimers & Dementia
- Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
- (2012) Rahul S. Desikan et al. ARCHIVES OF NEUROLOGY
- Blood-Based Protein Biomarkers for Diagnosis of Alzheimer Disease
- (2012) James D. Doecke ARCHIVES OF NEUROLOGY
- Age and Rate of Cognitive Decline in Alzheimer Disease
- (2012) Charles Bernick et al. ARCHIVES OF NEUROLOGY
- Use of FDG PET as an imaging biomarker in clinical trials of Alzheimer’s disease
- (2012) Karl Herholz Biomarkers in Medicine
- Alzheimer Mechanisms and Therapeutic Strategies
- (2012) Yadong Huang et al. CELL
- Randomized, Double-Blind, Parallel-Group, 48-Week Study for Efficacy and Safety of a Higher-Dose Rivastigmine Patch (15 vs. 10 cm2) in Alzheimers Disease
- (2012) Jeffrey Cummings et al. DEMENTIA AND GERIATRIC COGNITIVE DISORDERS
- SORL1 genetic variants and cerebrospinal fluid biomarkers of Alzheimer’s disease
- (2012) Liang-Hao Guo et al. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE
- The value and limitations of transgenic mouse models used in drug discovery for Alzheimer's disease: an update
- (2012) Kelly R Bales Expert Opinion on Drug Discovery
- Increasing the success rate for Alzheimer's disease drug discovery and development
- (2012) Robert E Becker et al. Expert Opinion on Drug Discovery
- Perspectives on molecular targeted therapies and clinical trials for neurodegenerative diseases
- (2012) Masahisa Katsuno et al. JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY
- Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010
- (2012) Thomas G. Beach et al. JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
- Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer's disease
- (2012) Guoxin Wu et al. JOURNAL OF NEUROSCIENCE RESEARCH
- The dynamics of Aβ distribution after γ-secretase inhibitor treatment, as determined by experimental and modelling approaches in a wild type rat
- (2012) Leon M. Tai et al. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS
- Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
- (2012) Reisa Sperling et al. LANCET NEUROLOGY
- Use of Biomarkers in Clinical Trials of Alzheimer Disease
- (2012) Liyong Wu et al. Molecular Diagnosis & Therapy
- Animal systems in the development of treatments for Alzheimer's disease: challenges, methods, and implications
- (2012) Jonathan J. Sabbagh et al. NEUROBIOLOGY OF AGING
- CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings
- (2012) T. T. Seppala et al. NEUROLOGY
- Injury markers predict time to dementia in subjects with MCI and amyloid pathology
- (2012) I. A. van Rossum et al. NEUROLOGY
- Clinical and Biomarker Changes in Dominantly Inherited Alzheimer's Disease
- (2012) Randall J. Bateman et al. NEW ENGLAND JOURNAL OF MEDICINE
- TREM2 Variants in Alzheimer's Disease
- (2012) Rita Guerreiro et al. NEW ENGLAND JOURNAL OF MEDICINE
- In Vivo Human Apolipoprotein E Isoform Fractional Turnover Rates in the CNS
- (2012) Kristin R. Wildsmith et al. PLoS One
- Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
- (2012) Dominic Holland et al. PLoS One
- Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Clifford R. Jack et al. Alzheimers & Dementia
- Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: Recommendations from the Alzheimer’s Association Research Roundtable Workgroup
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- Biomarkers in Alzheimer's disease drug development
- (2011) Jeffrey L. Cummings Alzheimers & Dementia
- Toward defining the preclinical stages of Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Reisa A. Sperling et al. Alzheimers & Dementia
- The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Guy M. McKhann et al. Alzheimers & Dementia
- The diagnosis of mild cognitive impairment due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease
- (2011) Marilyn S. Albert et al. Alzheimers & Dementia
- Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease
- (2011) Martin Farlow et al. BMC Neurology
- 18F-THK523: a novel in vivo tau imaging ligand for Alzheimer's disease
- (2011) M. T. Fodero-Tavoletti et al. BRAIN
- Neuroinflammation in Alzheimer's disease wanes with age
- (2011) Jeroen JM Hoozemans et al. Journal of Neuroinflammation
- Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study
- (2011) Melissa E Murray et al. LANCET NEUROLOGY
- Believe it or not: how much can we rely on published data on potential drug targets?
- (2011) Florian Prinz et al. NATURE REVIEWS DRUG DISCOVERY
- Fluorodeoxyglucose positron emission tomography: emerging roles in the evaluation of putative Alzheimer's disease-modifying treatments
- (2011) Eric M. Reiman NEUROBIOLOGY OF AGING
- Multimodal classification of Alzheimer's disease and mild cognitive impairment
- (2011) Daoqiang Zhang et al. NEUROIMAGE
- Chronic divalproex sodium use and brain atrophy in Alzheimer disease
- (2011) A. S. Fleisher et al. NEUROLOGY
- The three new pathways leading to Alzheimer's disease
- (2011) K. Morgan NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
- Alzheimer’s Disease Clinical Trials: Changing the Paradigm
- (2011) Jeffrey L. Cummings Current Psychiatry Reports
- Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease
- (2011) Randall J Bateman et al. Alzheimers Research & Therapy
- Requiring an amyloid-β1-42 biomarker may improve the efficiency of a study, and simulations may help in planning studies
- (2011) Suzanne B Hendrix Alzheimers Research & Therapy
- Requiring an amyloid-β1-42 biomarker for prodromal Alzheimer's disease or mild cognitive impairment does not lead to more efficient clinical trials
- (2010) Lon S. Schneider et al. Alzheimers & Dementia
- An Inherited Variable Poly-T Repeat Genotype in TOMM40 in Alzheimer Disease
- (2010) Allen D. Roses ARCHIVES OF NEUROLOGY
- What Can Be Inferred from the Interruption of the Semagacestat Trial for Treatment of Alzheimer's Disease?
- (2010) Jeffrey Cummings BIOLOGICAL PSYCHIATRY
- Blood-based biomarkers of Alzheimer’s disease: challenging but feasible
- (2010) Madhav Thambisetty et al. Biomarkers in Medicine
- Effectiveness and tolerability of high-dose (23 mg/d) versus standard-dose (10 mg/d) donepezil in moderate to severe Alzheimer's disease: A 24-week, randomized, double-blind study
- (2010) Martin R. Farlow et al. CLINICAL THERAPEUTICS
- Revising the definition of Alzheimer's disease: a new lexicon
- (2010) Bruno Dubois et al. LANCET NEUROLOGY
- 11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
- (2010) Juha O Rinne et al. LANCET NEUROLOGY
- Boosting power for clinical trials using classifiers based on multiple biomarkers
- (2010) Omid Kohannim et al. NEUROBIOLOGY OF AGING
- Reduced sample sizes for atrophy outcomes in Alzheimer's disease trials: baseline adjustment
- (2010) J.M. Schott et al. NEUROBIOLOGY OF AGING
- Biomarkers for Alzheimer's disease therapeutic trials
- (2010) Harald Hampel et al. PROGRESS IN NEUROBIOLOGY
- Defining and labeling disease-modifying treatments for Alzheimer's disease
- (2009) Jeffrey L. Cummings Alzheimers & Dementia
- A γ-secretase inhibitor decreases amyloid-β production in the central nervous system
- (2009) Randall J. Bateman et al. ANNALS OF NEUROLOGY
- Biomarkers in Alzheimer's Disease
- (2009) N Coley et al. Annals of the New York Academy of Sciences
- Advances in tau-focused drug discovery for Alzheimer's disease and related tauopathies
- (2009) Kurt R. Brunden et al. NATURE REVIEWS DRUG DISCOVERY
- A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
- (2009) S. Salloway et al. NEUROLOGY
- Disease-modifying therapies in Alzheimer’s disease
- (2008) Stephen Salloway et al. Alzheimers & Dementia
- Phase 2 Safety Trial Targeting Amyloid β Production With a γ-Secretase Inhibitor in Alzheimer Disease
- (2008) Adam S. Fleisher et al. ARCHIVES OF NEUROLOGY
- First Demonstration of Cerebrospinal Fluid and Plasma A Lowering with Oral Administration of a -Site Amyloid Precursor Protein-Cleaving Enzyme 1 Inhibitor in Nonhuman Primates
- (2008) S. Sankaranarayanan et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started